Dasatinib, 98%, a dual Bcr-Abl and Src family tyrosine kinase inhibitor with IC50s of 0.6, 0.8, 79 and 37 nM for Abl, Src, c-Kit and c-KitD816V, respectively

Name: Dasatinib, 98%, a dual Bcr-Abl and Src family tyrosine kinase inhibitor with IC50s of 0.6, 0.8, 79 and 37 nM for Abl, Src, c-Kit and c-KitD816V, respectively | 302962-49-8
Brand: J&K Chemical
SKU: JK923898_500_MG
Price: 299.0 USD
Availability: InStock

Cat. No JK923898_500_MG

Vendor: J&K Chemical

Product Information

Product Name

Dasatinib, 98%, a dual Bcr-Abl and Src family tyrosine kinase inhibitor with IC50s of 0.6, 0.8, 79 and 37 nM for Abl, Src, c-Kit and c-KitD816V, respectively

Brand Name

J&K

Product Number

923898

CAS

302962-49-8

SDS Document

View/Download

Certificate of Analysis (COA)

COA not found

General Information

PubChem CID

3062316

IUPAC Name

N-(2-chloro-6-methylphenyl)-2-6-4-(2-hydroxyethyl)piperazin-1-yl-2-methylpyrimidin-4-ylamino-1,3-thiazole-5-carboxamide

InChI Key

ZBNZXTGUTAYRHI-UHFFFAOYSA-N

SMILES

CC1=C(C(=CC=C1)Cl)NC(=O)C2=CN=C(S2)NC3=CC(=NC(=N3)C)N4CCN(CC4)CCO

Safety Information

Storage Condition

Freezer -20℃

References

Multi-omics reveals mechanism of Qi-Po-Sheng-Mai granule in reducing atrial fibrillation susceptibility in aged rats

Publication Name: Chinese Medicine

Publication Date: 2025-09-03

DOI: 10.1186/s13020-025-01154-6

The emerging role of Imatinib in malaria management: a review of evidence and future directions

Publication Name: Tropical Diseases, Travel Medicine and Vaccines

Publication Date: 2025-08-15

DOI: 10.1186/s40794-025-00257-0

[Management of side effects of CAR T cells]

Publication Name: Innere Medizin (Heidelberg, Germany)

Publication Date: 2025-08

DOI: 10.1007/s00108-025-01944-y

[CAR T cell therapy in acute lymphoblastic leukemia]

Publication Name: Innere Medizin (Heidelberg, Germany)

Publication Date: 2025-08

DOI: 10.1007/s00108-025-01949-7

Multi-omics analysis of zinc finger protein 683 as a prognostic biomarker for immune infiltration in clear cell renal cell carcinoma

Publication Name: BMC Cancer

Publication Date: 2025-07-29

DOI: 10.1186/s12885-025-14643-6

Dasatinib, 98%, a dual Bcr-Abl and Src family tyrosine kinase inhibitor with IC50s of 0.6, 0.8, 79 and 37 nM for Abl, Src, c-Kit and c-KitD816V, respectively

Product Information

General Information

Safety Information

References

Multi-omics reveals mechanism of Qi-Po-Sheng-Mai granule in reducing atrial fibrillation susceptibility in aged rats

The emerging role of Imatinib in malaria management: a review of evidence and future directions

[Management of side effects of CAR T cells]

[CAR T cell therapy in acute lymphoblastic leukemia]

Multi-omics analysis of zinc finger protein 683 as a prognostic biomarker for immune infiltration in clear cell renal cell carcinoma